16 results about "Anti angiogenic" patented technology

The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula I or a pharmaceutically acceptable salt, ester, solvate and / or prodrug thereof, wherein A, Q, n, m, R7, R8, V, X1, X2, X3, X4, X5, X6, and X7 are as defined herein, and at least one therapeutically active agents selected from immunotherapeutics, anticancer agents, and anti-angiogenics.

The present disclosure provides methods for assessing responsiveness or non-responsiveness to a therapeutic agent (e.g., ICB therapy and / or anti-angiogenic) in subjects having a cancer or tumor based on angio-immune panel signatures. The methods may further comprise identifying suitable treatment for the subject based on the angio-immune panel.

The application discloses a ROS / GSH responsive hyperbranched zwitterionic micelle and a preparation method and application thereof, and relates to a drug delivery system, ROS responsive zwitterionic micelles and GSH responsive zwitterionic micelles are prepared respectively, the ROS responsive zwitterionic micelles are loaded with anti-angiogenic drugs, and the GSH responsive zwitterionic micelles are loaded with anti-tumor stem cell drugs, so that the combined treatment of blood vessel normalization and tumor stem cell killing is realized, while the blood vessel normalization is realized, the restriction of the small intercellular gap of vascular endothelial cells caused by the blood vessel normalization on the enrichment and penetration of subsequent nano drugs in tumor sites is effectively solved, and the change of the interstitial pressure of tumor tissue caused by the blood vessel normalization is fully utilized to promote the deep penetration of small-size GSH responsive zwitterionic micelles into the internal region of the tumor, so that the killing of tumor stem cells is completed, and the combined treatment of the blood vessel normalization therapy and the tumor stem cell therapy is effectively realized.

This invention provides an integrated culture dish and method for dynamic mechanical stimulation and monitoring of live cells, belonging to the field of biotechnology, for simulating the effects of lung micromechanical processes on lung cancer cell growth and the production of anti-angiogenic drugs. It includes: a dish body; a culture medium having a tubular elastic membrane with an internal telescopic support, suspended at one end and with a magnetic traction plate at the other end. The elastic membrane has a first conductive region where only the outer layer is conductive, and a second conductive region where both the inner and outer layers are conductive and connected. Insulated conductors within a wire are electrically connected to the two regions respectively. A base is located on the underside of the dish body, and an adjustable magnet on it generates an adjustable attraction force on the magnetic traction plate. The elastic membrane is stretched and contracted by changes in magnetic force to apply mechanical stimulation to the attached cells. The resistance changes are monitored using the conductive regions and the dish body, thereby simulating the mechanical microenvironment of lung cancer cell growth and evaluating the effects of anti-angiogenic drugs.

The invention discloses an apatinib-immune synergistic nano-drug based on bacterial source vesicles as well as a preparation method and application of the apatinib-immune synergistic nano-drug. The nano-drug is Apatinib-MVs, and the nano-drug takes a membrane vesicle secreted by parabacteroides coumarini as a carrier to entrap an anti-angiogenesis drug apatinib; in-vitro anti-tumor experiment results show that the nano-drug can exert an efficient anti-tumor effect through a dual synergistic mechanism of inhibiting tumor angiogenesis and activating anti-tumor immune response at the same time.

This invention provides a 3-amino-5-phenyl-pyrazole derivative microtubule inhibitor, its preparation, and its pharmaceutical uses. The structure of the 3-amino-5-phenyl-pyrazole derivative is shown in formula (I): In formula (I), R1 is independently selected from 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, or dioxolane[1,3-d]phenyl; R2 and R3 are independently selected from methyl, methoxy, fluorine, chlorine, or bromine. This type of compound not only possesses strong antitumor activity but also anti-angiogenic effects, effectively inhibiting the proliferation of tumor cells and can be used to prepare tumor proliferation inhibitors. Furthermore, it has a strong ability to inhibit microtubule aggregation, providing a novel microtubule inhibitor for inhibiting tumor cell proliferation.

Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

This invention relates to the field of medical data analysis, and more particularly to a method for assessing the risk of pregnancy outcomes in pregnant women based on multifactor feature analysis. The method includes: acquiring individual measured time-series datasets and baseline reference data for physiological expectations; obtaining a gestational age-specific pathological surge penalty factor by weighting the ratio of angiogenic factors to anti-angiogenic factors; obtaining a cross-system pathological cascade time coupling factor by temporally tracing and coupling abnormal deviations in vascular system indicators and blood system indicators; obtaining a fused feature vector by correcting and fusing the initial linear regression slope features; and obtaining the pregnancy outcome risk assessment result by performing machine learning prediction on the fused feature vector. This method solves the problem that existing prediction methods based on linear regression slope extraction and feature splicing cannot effectively identify gestational age-specific early high-risk signals and cross-system short-term pathological cascade signals.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The antiangiogenic agent or polypeptide has an amino acid segment substantially similar to domain 1 of CD2. The polypeptide has a β-sheet formed by the two segments. Methods of using such agents and polypeptides are also included. The agent or polypeptide has a terminal glycine.

The application belongs to the field of biological medicine, and provides application of inosine in preparation of a drug for preventing and / or treating preeclampsia. The pathological state of preeclampsia is simulated by subcutaneous injection of a solution of nitroso-L-arginine methyl ester (125 mg / kg). From the 9th day of pregnancy, inosine is administered by gavage once a day (100 mg / kg), until the end of pregnancy. Compared with drugs such as labetalol, magnesium sulfate and other drugs with single treatment effect, the application proves that oral inosine can not only significantly improve hypertension and proteinuria caused by preeclampsia, repair placental function, promote intrauterine growth and development of the fetus, correct the imbalance of vascular and anti-angiogenic factors, but also reduce the damage to the kidneys and brain of pregnant women induced by preeclampsia, and exhibits a more comprehensive treatment effect, thereby providing a new therapeutic drug for preventing or treating preeclampsia.

The present application provides a kind of surface modified anti-angiogenic nano-assembly and its preparation method, the nano-assembly of the present application is modified grafting KK polypeptide by being grafted at the end of anti-VEGF functional polypeptide, enhance its electro-positive to promote penetration, while self-assembled with copper ion to form stable nanoparticles, the nanoparticles can effectively treat the inflammation reaction and vascular regeneration problem after eye alkali burn.Further by amide reaction access penetrating peptide and ROS scavenger TEMPO, by regulating ROS level, inhibit the activation of NF-κB signal pathway, so as to regulate the state of immune cells, clear oxidative stress, reduce tissue damage.The method of the present application is simple in operation, experimental condition is mild, and has higher ocular surface residence time and endocytosis efficiency, the obtained nanoparticles can be used for the treatment of eye alkali burn, has significant curative effect, especially suitable for the combined treatment of anti-angiogenesis and anti-oxidative stress, has extensive clinical application potential.

The application discloses application of rapamycin in preparation of a reliever of opiate drug tolerance caused by an anti-angiogenic drug, the reliever and a medicine, and relates to the technical field of medicine application. It is found that a TSC1-mTOR-autophagy axis plays a role in opiate drug tolerance caused by an anti-angiogenic drug, and the specific embodiment is that the anti-angiogenic drug can cause a decrease in TSC1 content, an mTOR / RPS6 pathway is activated, thereby autophagy flow is blocked, and pain sensation is enhanced; therefore, the opiate tolerance condition can be relieved by adjusting the mTOR / RPS6 pathway through rapamycin.

The invention discloses a preparation method for realizing safe and effective antibacterial gene therapy of colorectal cancer by combining antibiosis and anti-tumor, and belongs to the field of drug carrier materials. The preparation method comprises the following steps: modifying lauric acid (LA) resisting fusobacterium nucleatum (Fn) and a targeting molecule 4-carboxyphenylboronic acid (PBA) into low-molecular-weight polyethyleneimine (OEI), and self-assembling with LA to obtain LA-OLP (AFs); the AFs is compounded with an anti-angiogenesis gene (sFlt-1), and the AFs and distearoyl phosphatidyl ethanolamine-methoxy polyethylene glycol (DSPE-mPEG) are co-assembled to obtain the nano particle LA (at) OLP / sFlt-1 / DSPE-mPEG (AFGTs-PEG). The method has the advantages of low cost and simple and feasible process flow, can be widely applied to the fields of materials science, biology, medicine and the like, and cooperates with antibacterial and anti-angiogenic gene therapy to enhance gene therapy on colorectal cancer.

A number of anti-angiogenic strategies connected with the VEGF signalling pathway are used in current clinical treatment or trial phase, but they either cause adverse effects or are not specific. Various strategies were aimed at identifying peptides inhibiting the VEGF-A165 / NRP-1 interaction. A well-known antiangiogenic peptide is the heptapeptide termed “A7R” having the amino acid sequence ATWLPPR, for which various derivatives have been synthesized, which include peptides having the general sequence Lys(hArg)-AA2-AA3-Arg. However, the ability of the known peptides to inhibit the VEGF-A165 / NRP-1 interaction was too low for their use as candidate drugs for inhibiting angiogenesis in subjects in need thereof. The present inventors have now conceived a family of novel peptide-like compounds having a nanomolar affinity for NRP-1, which are thus endowed with a powerful capacity to inhibit the VEGF-A165 / NRP-1 interaction. These novel peptide-like compounds may be relevantly used as antiangiogenic compounds, especially in subjects affected with cancer.

Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.